๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca62 First Affiliated Hospital of Fujian Medical University45 Merck Sharp & Dohme LLC39 Fujian Medical University Union Hospital39 Fujian Cancer Hospital35
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Fuzhou

1018 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab Deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-08-07
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
DrugsJAB-3312·Glecirasib·Pemetrexed·Carboplatin
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
Recruiting
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
NCT06496490Non-Small Cell Lung Cancer
DrugsTQB2102·Etoposide
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Recruiting
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
NCT06487455Advanced Solid Tumor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
NCT06421142Urinary Bladder Neoplasms
First Affiliated Hospital of Fujian Medical University
Not applicable
80
Fuzhou
2024-08-02
Recruiting
68Ga-NI-FAPI PET/CT: First-in-human Study
NCT06688305Malignant Neoplasm
Drug68Ga-NI-FAPI
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
40
Fuzhou
2024-08-01
Recruiting
THBC/CGF for Alveolar Bone Regeneration: A Real-World Study
NCT07779421Alveolar Bone Loss, Alveolar Ridge Resorption After Extraction, Tooth, Impacted
Stomatological Hospital Affiliated with Fujian Medical University
Not applicable
136
Fuzhou
2024-08-01
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsCamizestrant·Saruparib·Anastrozole·Exemestane
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Active, closed
Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke
NCT06360458Acute Ischemic Stroke, Large Infarct Core
DrugMethylprednisolone sodium succinate
Wan-Jin Chen
Phase 3
928
Hefei, Taihe Chengguanzhen, Wuhu, Anxi, Fuqing, Fuzhou, Longyan, Nanping
2024-08-01
Active, closed
Predicting HIF-2ฮฑ Levels in Clear Cell Kidney Cancer Using Machine Learning
NCT07332923Renal Clear Cell Carcinoma, HIF-2ฮฑ, Radiomics, Nomogram
First Affiliated Hospital of Fujian Medical University
Observational
500
Fuzhou
2024-08-01
By invitation
The Construction and Application of a Mobile Health Management Program for Elderly Depression Based on the Patterns of Cognitive Function Changes
NCT06709027Patients With Depression in the Elderly
Fujian Medical University
Not applicable
80
Fuzhou
2024-08-01
Not yet open
Electroacupuncture Treatment of Behavioral and Psycological Symptoms in Patients With Alzheimer's Disease
NCT06523309BPSD (Behavioral and Psycological Symptoms of Dementia), Alzheimer's Dementia
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Observational
1,000
Beijing, Fuzhou, Harbin
2024-07-30
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Recruiting
PulseSelectโ„ข PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, รœrรผmqi
2024-07-23
Recruiting
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
NCT06351150Vasodilatory Shock
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
214
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsBevacizumab·Tislelizumab
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490Biliary Tract Cancer
DrugTQB2102
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Not yet open
Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease
NCT06495957Agitation Associated With Alzheimer's Dementia, Alzheimer's Dementia
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
224
Beijing, Fuzhou, Harbin
2024-07-20
Recruiting
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
NCT06413654Neuromyelitis Optica Spectrum Disorders
DrugB001
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Recruiting
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
NCT06434597Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
DrugSPH5030
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
60
Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-07-17
Recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Generalized Myasthenia Gravis
DrugTelitacicept
Vor Biopharma
Phase 3
180
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan
2024-07-17
Recruiting
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
NCT06559696Breast Cancer
Fujian Medical University Union Hospital
Phase 3
722
Fuzhou
2024-07-15
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang
2024-07-12
Recruiting
A Clinical Study of B007 in the Treatment of Pemphigus.
NCT06454357Pemphigus
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Recruiting
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
NCT06601309Esophageal Squamous Cell Carcinoma
DrugsSerplulimab·Cisplatin·Paclitaxel
Fujian Medical University Union Hospital
Phase 2
90
Fuzhou
2024-07-11
Recruiting
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
NCT06434610Platinum-resistant Recurrent Ovarian Cancer
DrugPaclitaxel
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2
90
Beijing, Bengbu, Changsha, Fuzhou, Guangzhou, Jinan, Kunming, Nanning
2024-07-11
Recruiting
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
NCT06235203Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
154
Shanghai, Fuzhou, Nanning, Shenzhen
2024-07-09
Active, closed
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
NCT06372925Plaque, Atherosclerotic
DrugsInclisiran·Atorvastatin
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Recruiting
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
NCT06643208Intrahepatic Cholangiocarcinoma
Fujian Provincial Hospital
Observational
37
Fuzhou
2024-07-01
Not yet open
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
NCT06475599Endometrial Cancer
DrugsAnlotinib hydrochloride·Etoposide
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
420
Hefei, Fuzhou, Lanzhou, Guangzhou, Huizhou, Jiangmen, Meizhou, Guigang
2024-07
Active, closed
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
DrugsIBI343·Irinotecan·Paclitaxel
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Bengbu, Hefei, Lu'an, Wuhu, Beijing, Fuzhou, Lanzhou, Dongguan
2024-06-30
Recruiting
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
NCT06734572Malignant Neoplasm
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
5
Fuzhou
2024-06-25
Recruiting
Personalized Interventions Via Health Portraits in Mild Behavioral Impairment
NCT06416514Neurocognitive Disorders
Fujian Provincial Hospital
Not applicable
60
Fuzhou
2024-06-25
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Cangzhou, Shijiazhuang, Harbin
2024-06-25
Recruiting
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
NCT06228079Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
176
Shanghai, Fuzhou, Nanning, Shenzhen
2024-06-25
Recruiting
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
NCT06536400Solid Tumors
DrugHSK42360
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
316
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guiyang, Shijiazhuang
2024-06-25
Active, closed
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT06378177Head and Neck Squamous Cell Carcinoma
DrugsPaclitaxel·Tislelizumab
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
Recruiting
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
NCT06791083Gastric Cancer
DrugsEnvafolimab·Fruquintinib
First Affiliated Hospital of Fujian Medical University
Phase 2
40
Fuzhou
2024-06-20
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
DrugsLevoleucovorin·Leucovorin·Sacituzumab tirumotecan·Cisplatin
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
NCT07584954Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy
Jun Zhou
Phase 1
90
Fuzhou, Anyang, Jinan, Shanghai
2024-06-18
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Active, closed
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621Triple Negative Breast Cancer(TNBC)
DrugsPumitamig·Nab-paclitaxel
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Recruiting
Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia
NCT06442943Cognitive Dysfunction
Fujian Provincial Hospital
Not applicable
128
Fuzhou
2024-06-04
Not yet open
Henagliflozin's Impact on Prediabetes Remission
NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders
DrugHenagliflozin
Shandong Provincial Hospital
Phase 4
984
Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen
2024-06
Not yet open
A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B
NCT06452693Hepatitis B, Chronic
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
162
Bengbu, Fuzhou, Lanzhou, Guangzhou, Nanning, Guiyang, Harbin, Shiyan
2024-06
Active, closed
Effect of Preoperative Individualized Education on Anxiety and Recovery.
NCT06419088Education
Fujian Medical University Union Hospital
Not applicable
156
Fuzhou
2024-05-30
Recruiting
Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases
NCT06520774Aortic Arch Aneurysm, Penetrating Aortic Ulcer
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
103
Beijing, Changsha, Chengdu, Fuzhou, Hanzhou, Kunming, Nanjing, Shanghai
2024-05-30
Recruiting
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT06445088Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
DrugsAnvumetostat·Modified FOLFIRINOX·RMC-6236·Nab-paclitaxel
Amgen
Phase 1
120
Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun
2024-05-29
Recruiting
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
NCT06387082Hematological Malignancies
Hutchmed
Phase 1
132
Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan
2024-05-27
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou
2024-05-24
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Recruiting
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
NCT06607419B-Cell Lymphoblastic Leukemia
DrugBlinatumomab
Shanghai Jiao Tong University School of Medicine
Phase 2/3
90
Hefei, Fuzhou, Shanghai, Ningbo
2024-05-21
Recruiting
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06415669Gastric/Gastroesophageal Junction Adenocarcinoma
DrugsApatinib Mesylate·Adebrelimab·Paclitaxel
The First Affiliated Hospital of Xiamen University
Phase 2
30
Fuzhou
2024-05-19
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naรฏve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138Hematologic Malignancies
DrugsICP-248·Orelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
NCT07234162Peripheral T-cell Lymphoma
Dizal Pharmaceuticals
Phase 3
218
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-05-13
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan
2024-05-08
Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888Metastatic Pancreatic Cancer
DrugsSurufatinib·Nab-paclitaxel·Gemcitabine
Hutchmed
Phase 2/3
502
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Nanning, Guandong
2024-05-08
Recruiting
AMT-116 in Patients with Solid Tumors
NCT06782334Advanced Solid Tumors
DrugAMT-116
Multitude Therapeutics Inc.
Phase 1/2
144
Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou
2024-05-07
Recruiting
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
NCT06406816Intrahepatic Cholangiocarcinoma
Yongyi Zeng
Phase EARLY_PHASE1
10
Fuzhou
2024-05-06
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
450
Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang
2024-05-03
Recruiting
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
NCT06592417Advanced Malignant Solid Tumor
DrugJSKN016
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
140
Fuzhou, Guangzhou
2024-04-30
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLY3650150
Eli Lilly and Company
Phase 3
510
Beijing, Bengbu, Changsha, Chengdu, Foshan, Fuzhou, Guangdong, Haikou
2024-04-29
Recruiting
Cognitive Leisure and Preclinical Alzheimer's Disease: Exploring Neural Mechanisms
NCT06215274Cognitive Dysfunction
Yuanjiao Yan
Observational
156
Fuzhou
2024-04-27
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069Acute Myeloid Leukemia
DrugHMPL-306
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Active, closed
Evolve China PMCF Study
NCT06368622Intracranial Aneurysm
Stryker Neurovascular
Observational
500
Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao
2024-04-24
Recruiting
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
NCT06349317Hepatocellular Carcinoma
Yongyi Zeng
Phase 2
33
Fuzhou
2024-04-22
Active, closed
A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors
NCT07104877Colorectal Cancer, Gastric Cancer (GC), Gastrointestinal Tumors
DrugSYS6010
Fujian Cancer Hospital
Not applicable
25
Fuzhou
2024-04-18
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Beijing, Changsha, Cheng Du Shi, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2024-04-18
Active, closed
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
NCT06394414Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
DrugEfgartigimod
argenx
Phase 3
119
Beijing, Changchun, Chongqing, Fuzhou, Guangxi, Guangzhou, Guiyang, Ningbo
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot
2024-04-16
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
DrugsBevacizumab·Tislelizumab
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Recruiting
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
NCT06363825Advanced Hepatocellular Carcinoma
DrugTislelizumab
Fujian Medical University
Phase 2
57
Fuzhou
2024-04-12
Recruiting
Adebrelimab ยฑInduction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
NCT06510660Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
DrugAdebrelimab
Fujian Medical University Union Hospital
Phase 2
48
Fuzhou
2024-04-11
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Dato-DXd·Rilvegostomig·Pembrolizumab
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Gemcitabine·Pemetrexed·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
Recruiting
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
NCT06241781Adult
Grit Biotechnology
Phase 2
83
Beijing, Fuzhou, Shenzhen, Guilin, Haโ€™erbin, Luoyang, Zhengzhou, Wuhan
2024-04-02
Recruiting
pBFS Guided rTMS Over Cognitive Control Network for ASD
NCT06255535Autism Spectrum Disorder
Changping Laboratory
Not applicable
215
Fuzhou, Baoding, Xi'an, Jining, Linyi
2024-04-01
Recruiting
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
NCT06280105Hepatocellular Carcinoma
DrugsRegorafenib·Cadonilimab
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase 2
40
Fuzhou
2024-03-31
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543Esophagus Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Recruiting
Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)
NCT06284642Aneurysmal Subarachnoid Hemorrhage
DrugUrokinase
Second Affiliated Hospital of Nanchang University
Phase 4
424
Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-03-28
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Recruiting
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
NCT06463834Esophageal Squamous Cell Carcinoma
DrugTislelizumab
Fujian Cancer Hospital
Phase 2
30
Fuzhou
2024-03-20
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-03-04
Recruiting
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
NCT06314334Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
DrugsGelad·P-Gemox·Pegaspargase·Tislelizumab
Fudan University
Phase 2
210
Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo
2024-03-04
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
DrugsCapecitabine·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery
NCT06254859Thyroid Cancer, Thyroid Cancer, Papillary
Fujian Medical University
Observational
100
Fuzhou
2024-03-01
Recruiting
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
NCT06438250Malignant Neoplasm
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
5
Fuzhou
2024-03-01
Recruiting
68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
NCT06740240Tumor
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
30
Fuzhou
2024-03-01
Rows per page Showing 501–600 of 1018
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,018 of those studies with a site in Fuzhou.

How many clinical trials are recruiting in Fuzhou?

594 of the 1,018 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 114 have not yet opened recruitment, 287 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.